DCF Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

DCF Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,300	Closed	-$249K	–	84
2023 Q4	$249K	Sell	1,300 -500	-28%	-$85.2K	0.14%	69
2023 Q3	$319K	Buy	1,800 +200	+13%	+$38.2K	0.17%	69
2023 Q2	$304K	Buy	1,600 +200	+14%	+$39.7K	0.16%	75
2023 Q1	$280K	Hold	1,400	–	–	0.17%	57
2022 Q4	$333K	Hold	1,400	–	–	0.22%	54
2022 Q3	$280K	Sell	1,400 -3,600	-72%	-$687K	0.18%	65
2022 Q2	$729K	Sell	5,000 -14,000	-74%	-$1.99M	0.43%	44
2022 Q1	$3.1M	Buy	19,000 +1,000	+6%	+$152K	1.36%	21
2021 Q4	$3.05M	Buy	18,000 +500	+3%	+$92.9K	1.24%	23
2021 Q3	$3.3M	Hold	17,500	–	–	1.46%	22
2021 Q2	$2.97M	Sell	17,500 -2,500	-13%	-$366K	1.05%	25
2021 Q1	$2.82M	Hold	20,000	–	–	1.23%	24
2020 Q4	$2.6M	Sell	20,000 -7,500	-27%	-$1M	1.07%	27
2020 Q3	$4M	Hold	27,500	–	–	2.05%	17
2020 Q2	$4.07M	Sell	27,500 -1,500	-5%	-$202K	2.28%	13
2020 Q1	$3.16M	Sell	29,000 -11,000	-28%	-$1.27M	2.07%	16
2019 Q4	$4.61M	Buy	+40,000	New	+$3.99M	2.92%	11

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCF Advisers's ALNY Position: Q1 2024 in Review

DCF Advisers sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 1,300 shares — an estimated $249K sold.

DCF Advisers first reported a position in ALNY in Q4 2019 and held it in 17 quarters. The position peaked at $4.61M in Q4 2019. 499 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

DCF Advisers reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
DCF Advisers sold 1,300 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $249K.
DCF Advisers first reported a position in Alnylam Pharmaceuticals in Q4 2019 and held it in 17 quarters.
DCF Advisers's Alnylam Pharmaceuticals position peaked at $4.61M in Q4 2019.
499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on DCF Advisers's 13F filing for Q1 2024, filed 15 May 2024.